Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a ...

Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...

A UPMC pulmonologist discusses RSV, including what the symptoms are, who is most at risk and how effective the vaccine is.

The Californian brand reveals the latest generation of its massively popular Hightower, but it's tweaks, nips and tucks ...

Administering the respiratory syncytial virus (RSV) in older adults with underlying health conditions may be a cost-effective ...

As RSV approaches, some "real world" data out of France provides even more support for the RSV antibody shot for babies.

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...